Clinical

This year’s most-read respiratory articles explored a variety of topics, including the effects of marijuana and vaping on the lungs.

Understanding these relationships is crucial for developing effective clinical management strategies for patients with AD, according to a recent literature review.

The FDA approved the first test to assess opioid addiction risk; Americans are using more cold and allergy medicines to mask any related symptoms to return to work and social gatherings, but may be overtreating themselves in the process; Rite Aid will be banned from using artificial intelligence–powered facial recognition technology for 5 years under a proposed Federal Trade Commission settlement.

Increased pulmonary arterial hypertension (PAH) awareness and earlier screening in routine clinical practice could provide an opportunity for earlier treatment, resulting in reduced economic burden for payers, employers, and society at large.

Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) has become the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States.

Therapeutic and financial considerations of EVT are explored by a medical expert.

An expert panel unpacks challenges in implementing bispecific therapies for operational excellence.

Dr Haumschild leads a discussion highlighting key care team members shaping the bispecific therapy decision-making processes.

These findings suggest that addressing socioeconomic disparities and inequities that impact access to health care and services may help improve survival outcomes across racial/ethnic groups of male patients with early breast cancer.

A panel of medical experts break down the pathophysiology and current treatment landscape surrounding Ph+ ALL.

Most studies involving the treatment of psoriasis do not contain any images of patients, a review finds.

The researchers explained that future studies should explore how the physical, emotional, and social impact of hepatitis B on patients could be measured and incorporated into clinical management.

Patients who had concurrent thrombotic thrombocytopenic purpura (TTP) and COVID-19 had elevated risk of mortality and other complications.

In the phase 3 EV-302/KEYNOTE-A39 clinical trial, the antibody-drug conjugate enfortumab vedotin plus PD-1 inhibitor pembrolizumab nearly doubled both median overall survival and progression-free survival compared with chemotherapy.

David Fajgenbaum, MD, MBA, MSc, cofounder of Every Cure, shared that the organization is able to reduce clinical trial costs to $1 to $5 million per drug trial, and that clinical trials are not always necessary to expand a drug's indication.

In our coverage of myasthenia gravis this year, the top developments show the effects of COVID-19 continue to be uncovered, a new FDA approval for generalized disease, and assessing patient outcomes following uncontrolled disease and respiratory distress.

Two doses of batoclimab were evaluated for their effectiveness in patients with generalized myasthenia gravis (MG) who were seropositive.

Kevan Herold, MD, professor of immunobiology and medicine at Yale School of Medicine, discussed recently published results from the PROTECT trial of teplizumab in patients newly diagnosed with type 1 diabetes (T1D).

Also known as Sanfilippo syndrome, this rare genetic syndrome has no known cures and what current treatment options are available are expensive and limited in supply.

A vaccine is showing promising results in treating melanoma; the Biden administration will implement inflation penalties on dozens of drugmakers to reduce out-of-pocket costs for Medicare recipients; the CDC issued an alert urging health care providers to increase immunization coverage for influenza, COVID-19, and respiratory syncytial virus (RSV).

Trastuzumab administered subcutaneously delivered unique immunomodulation effects vs intravenous trastuzumab in patients with treatment-naïve HER2-positive (HER2+) breast cancer

Givinostat, a histone deacetylase inhibitor from Italfarmaco, was supported by data from the phase 3 EPIDYS study, a randomized, double-blind, placebo-controlled, multicenter trial investigating the agent vs placebo.

The treatment developed by Amgen could be the first therapeutic option approved for third-line treatment of advanced small cell lung cancer (SCLC).

Skeletal muscle proved to be significant in calculating chemotherapy toxicities in nonmetastatic colorectal cancer (CRC).

Mark Metersky, MD, FCCP, illustrates the pathology of bronchiectasis.